Cutia Therapeutics (HKSE:02487) Cash And Cash Equivalents : HK$411.8 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Cash And Cash Equivalents?

Cutia Therapeutics's quarterly cash and cash equivalents declined from Dec. 2023 (HK$517.49 Mil) to Jun. 2024 (HK$297.18 Mil) but then increased from Jun. 2024 (HK$297.18 Mil) to Dec. 2024 (HK$411.77 Mil).

Cutia Therapeutics's annual cash and cash equivalents declined from Dec. 2022 (HK$520.24 Mil) to Dec. 2023 (HK$517.49 Mil) and declined from Dec. 2023 (HK$517.49 Mil) to Dec. 2024 (HK$411.77 Mil).

Cutia Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Cutia Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Cash And Cash Equivalents Chart

Cutia Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

248.73

520.24

517.49

411.77

Cutia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial			520.24	758.60	517.49	297.18	411.77

Cutia Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Cutia Therapeutics (HKSE:02487) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Cutia Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070

Website

https://www.cutiatx.com

Cutia Therapeutics is a dermatology focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.

Executives

Zhang Lele	2101 Beneficial owner
Zhang Qiping	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p.	2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Yf Dermatology Limited	2101 Beneficial owner
Yunfeng Capital Limited	2102 Investment manager
Yunfeng Fund Iii, L.p.	2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd.	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you

Cutia Therapeutics Headlines

No Headlines